T. Rowe Price Associates
BHVN

T. Rowe Price Associates’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

T. Rowe Price Associates’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-356,257
Closed -$53.9M – 3064
2022
Q3 		$53.9M Sell
356,257
-165,323
-32% -$24.5M 0.01% 629
2022
Q2 		$76M Buy
521,580
+5,809
+1% +$742K 0.01% 742
2022
Q1 		$61.2M Buy
515,771
+49,794
+11% +$6.21M 0.01% 900
2021
Q4 		$64.2M Buy
465,977
+41,760
+10% +$5.31M 0.01% 909
2021
Q3 		$58.9M Buy
424,217
+53,488
+14% +$6.68M 0.01% 952
2021
Q2 		$36M Buy
370,729
+216,182
+140% +$17.5M ﹤0.01% 1144
2021
Q1 		$10.6M Sell
154,547
-169
-0.1% -$13.7K ﹤0.01% 1387
2020
Q4 		$13.3M Buy
154,716
+128,840
+498% +$10.9M ﹤0.01% 1309
2020
Q3 		$1.68M Buy
25,876
+366
+1% +$24K ﹤0.01% 1598
2020
Q2 		$1.86M Sell
25,510
-728
-3% -$38.7K ﹤0.01% 1552
2020
Q1 		$893K Buy
26,238
+462
+2% +$21.1K ﹤0.01% 1749
2019
Q4 		$1.4M Buy
25,776
+2,846
+12% +$141K ﹤0.01% 1742
2019
Q3 		$957K Buy
22,930
+4,099
+22% +$173K ﹤0.01% 1841
2019
Q2 		$825K Buy
+18,831
New +$1.06M ﹤0.01% 1917
2018
Q1 		– Sell
-375,048
Closed -$10.1M – 2649
2017
Q4 		$10.1M Buy
375,048
+1,100
+0.3% +$30.3K ﹤0.01% 1341
2017
Q3 		$14M Sell
373,948
-122,180
-25% -$3.71M ﹤0.01% 1280
2017
Q2 		$12.4M Buy
+496,128
New +$11.4M ﹤0.01% 1281

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

T. Rowe Price Associates's BHVN Position: Q4 2022 in Review

T. Rowe Price Associates sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 356,257 shares — an estimated $53.9M sold.

T. Rowe Price Associates first reported a position in BHVN in Q2 2017 and held it in 17 quarters. The position peaked at $76M in Q2 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • T. Rowe Price Associates reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 356,257 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $53.9M.
  • T. Rowe Price Associates first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 17 quarters.
  • T. Rowe Price Associates's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $76M in Q2 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on T. Rowe Price Associates's 13F filing for Q4 2022, filed 14 Feb 2023.